Comments

Coherus Oncology Stock Guidance

CHRSNASDAQ
Logo brought to you by Benzinga Data
Trade with Public
Trade with Public
$1.39
0.042.96%
At close: Dec 15, 4:00 PM EST
$1.38
-0.01-0.72%
After Hours: 4:12 PM EST
OverviewNewsEarningsOptions

Guidance

Analyst RatingsInsider TradesShort InterestGovernment TradesStock Report

Coherus Oncology Stock Guidance | NASDAQ:CHRS | Benzinga

Coherus Oncology issues guidance on future EPS and revenue, giving investors insight into how much the company expects to earn in upcoming periods.

Get Alert
01/13/2025CHRS
Coherus BioSciences
FY2024———$255.00M$260.00M$255.58MGet Alert
01/13/2025CHRS
Coherus BioSciences
Q42024———$49.00M$54.00M$43.88MGet Alert
01/10/2024CHRS
Coherus BioSciences
Q42023———$90.00M—$95.68MGet Alert
01/10/2024CHRS
Coherus BioSciences
FY2023———$260.00M$260.00M$260.53MGet Alert
11/06/2023CHRS
Coherus BioSciences
FY2023———$250.00M$260.00M$288.19MGet Alert
08/02/2023CHRS
Coherus BioSciences
FY2023———$275.00M—$266.16MGet Alert
05/08/2023CHRS
Coherus BioSciences
FY2023———$275.00M—$344.75MGet Alert

FAQ

Q

What is the most recent guidance for Coherus Oncology (CHRS)?

A

There have been no specific sales or earnings guidance reported for Coherus Oncology in recent months.

Browse guidance and forecast on all stocks.

People Also Watch

Molecular Partners AG
NASDAQ:MOLN
$4.02
-1.59%
Kalaris Therapeutics Inc
NASDAQ:KLRS
$8.67
2.00%
Innate Pharma SA
NASDAQ:IPHA
$1.88
1.08%
Gain Therapeutics Inc
NASDAQ:GANX
$4.01
1.57%
Burning Rock Biotech Ltd
NASDAQ:BNR
$15.71
-0.32%
Vistagen Therapeutics Inc
NASDAQ:VTGN
$4.42
0.68%
Sangamo Therapeutics Inc
NASDAQ:SGMO
$0.44
1.11%
Genelux Corp
NASDAQ:GNLX
$4.16
1.96%
Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2025 Benzinga | All Rights Reserved